Desferrioxamine improves burst-forming unit-erythroid (BFU-E) proliferation in haemodialyis patients

Nephrology Dialysis Transplantation

Volumn 13, Issue 5, 1998, Pages 1194-1199

  Aucella, Filippo ^a   Vigilante, Mimmo ^a   Scalzulli, Potito ^a   Musto, Pellegrino ^a   Crisetti, Annalisa ^a   Modoni, Sergio ^a   Carotenuto, Mario ^a   Stallone, Carmine ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

Desferrioxamine; Erythroid progenitors; Erythropoiesis; Haemodialysis

Indexed keywords

ALUMINUM; DEFEROXAMINE; DEFEROXAMINE MESYLATE; FERRITIN; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; TRANSFERRIN RECEPTOR;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD SAMPLING; BURST FORMING UNIT E; CELL CULTURE; CELL PROLIFERATION; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; DENSITY GRADIENT CENTRIFUGATION; ERYTHROCYTE; ERYTHROPOIESIS; FEMALE; HEMATOCRIT; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; IRON STORAGE; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; RETICULOCYTE; STEM CELL; TIME;

AGED; AGED, 80 AND OVER; CELL DIVISION; DEFEROXAMINE; ERYTHROID PROGENITOR CELLS; FEMALE; HUMANS; INTERLEUKIN-1; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031980826     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/13.5.1194     Document Type: Article

References (36)

1. O'Hara JA, Murnagham DJ. Reversal of aluminum-induced hemodialysis anemia by low-aluminum dialysate. N Engl J Med 1982; 306: 654-656
2. Esbach JW, Adamson JW. Recombinant human erythropoietin: implications for nephrology. Am J Kidney Dis 1988; 11: 203-209
3. De Broe ME, D'Haese PC, Couttenye M-M et al. New insight and strategies in the diagnosis and treatment of aluminium overload in dialysis patients, Nephrol Dial Transplant 1993; 8 [Suppl 1]: 47-50
4. Casati S, Castelnovo C, Campise M, Ponticelli C. Aluminium interference in the treatment of hemodialysis patients with recombinant human erythropoietin. Nephrol Dial Transplant 1990; 5: 441-443
5. Altman P. Aluminium toxicity in dialysis patients, no evidence for a threshold serum aluminium concentration. Nephrol Dial Transplant 1993; 8 [Suppl 1]: 25-34
6. Consensus Conference. Diagnosis and treatment of aluminium overload in end-stage renal failure patients. Nephrol Dial Transplant 1993; 8 [Suppl 1]: 1-4
7. Giordano N, Fioravanti A, Sancasciani S, Marcolongo R. Increased storage of iron and anaemia in rheumatoid arthritis. Usefulness of desferrioxamine. Br Med J 1984; 289: 961-962
8. Ekert H, Rawlinson I. Desferoxamine and favism. N Engl J Med 1985; 312: 1260
9. Jensen PD, Heickendorff L, Pedersen B et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol 1996; 94: 288-299
10. Romero R, Novoa D, Otero S et al. Direct effect of desferoxamine on hemoglobin synthesis in patients on hemodialysis treated with recombinant human erythropoietin. Nephron 1993; 63: 164 167
11. Praga M, Andres A, de La Sema J et al. Improvement of anaemia with desferrioxamine in haemodialysis patients. Nephrol Dial Transplant 1987; 2: 243-247
12. Drueke T, Basile C. Desferrioxamine, anaemia and haemodialysis. Lancet 1988; 1: 1405-1406
13. Basile C, Scatizzi A. Desferrioxamine does not improve aluminium-unrelated anaemia of haemodialysis. Nephrol Dial Transplant 1988; 3: 355
14. Freshney MG. Colony forming assays for CFC-GM, BFU-E, CFC-GEMM and CFC-MIX. In: Freshney RI, Pragnell IB, Freshney MG, ed. Culture of Hemopoietic Cells. Raven Press, New York: 1994: 265-268
15. Musto P, Modoni S, Alicino G et al. Modifications of erythropoiesis in myelodysplastic syndromes treated with recombinant erythropoietin as evaluated by soluble transferrin receptor, high fluorescence reticulocytes and hypochromic erythrocytes. Haematologica 1994; 79: 493-499
16. Beguin Y. The soluble transferrin receptor as a new index of erythropoiesis. Haematologica 1992; 77: 1-10
17. Means RT, Krants SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1994; 7: 1639-1647
18. De La Serna J, Praga M, Gilsanz F et al. Improvement in the erythropoiesis of chronic haemodialysis patients with desferrioxamine. Lancet, 1988; 1: 1009-1011
19. Editorial. Metal chelation therapy, oxygen radicals,and human disease. Lancet 1985; 1: 143-145
20. Wang GL, Semenza GL. Desfenioxamine induces erythropoietin gene expression and hypoxia-inducible facror 1 binding activity: implication for models of hypoxia signal transduction. Blood 1993; 82: 3610-3615
21. Testa U, Louache F, Thompoulos P, Rochant H. The iron chelating agent picolinic acid enhances transferrin receptor expression in human erythroleukaemic cell lines. Br J Haematol 1985; 60: 491-502
22. Goldberg MA, Schneider THJ. Similarities between the oxygen sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J Biol Chem 1994; 269: 4355-4359
23. Timeus F, Valle P, Crescenzio N et al. Effect of desferrioxamine and hydroxypyridones on hemopoietic progenitors and neuroectodermal tumor cells. Am J Hematol 1994; 47: 183-188
24. Aucella F, Vigilante M, Piemontese M, Scalzulli P et al. Synergy of rHuEpo and desferrioxamine (DFO) on erythroid precursors proliferations in dialysis. Nephrol Dial Transplant 1997; 12 (9): A191 (abstract)
25. Klausner RD, Rouault TA, Harfor JB. Regulating the fate of mRNA. the control of cellular iron metabolism. Cell 1993; 72: 19-28
26. King PJ, Dragsten PR, Roberts RA et al. Iron deprivation increases erythropoietin production in vitro, in normal subjects and patients with malignancy. Br J Haematol 1996; 95: 241-248
27. Vreugdenhil G, Smeets M, Feelders RA van Eijk HG. Iron chelators may enhance erythropoiesis by increasing iron delivery to haematopoietic tissue and erythropoietin response in iron-loading anaemia. Acta Haematol 1993; 89: 57-60
28. Khan S, O'Brian PJ. Modulating hypoxia-induced hepatocyte injury by affecting intracellular redox state. Biochem Biophys Acta 1995; 1269 (2): 153-161
29. Fandrey J, Frede S; Ehleben W et al. Cobalt chloride and desferrioxamine antagonize the inhibition of erythropoietin production by reactive oxigen species. Kidney Int 1997; 51: 492-496
30. Jelkmann W, Pagel H, Hellwig T, Fandrey J. Effects of antioxidant vitamins on renal and hepatic erythropoietin production. Kidney Int 1997; 51: 497-501
31. Tracey KJ, Wei H, Manogue KR et al. Cachectin/tumor necrosis factor induces cachexia, anemia and inflammation. J Exp Med 1988; 1 67: 1211
32. Schooley JC, Kullgren B, Allison AC. Inhibition by interleukin-1 of the action of erythropoietin on erythroid precursors and its possible role in the pathogenesis of hypoplastic anaemia. Br J Haematol 1987; 67: 11
33. Johnson CS, Keckler DJ, Topper MI et al. In vivo hematopoietic effects of recombinant interleukin-1α in mice. Stimulation of granulocytic, monocytic, megakaryocytic and early erythroid progenitors, suppression of late erythroid progenitors, and reversal of erythroid suppression with erythropoietin. Blood 1989; 73: 678
34. Means RT, Krantz SB. Inhibition of human erythroid colonyforming unit by tumor necrosis factor is mediated by β interferon. Clin Res 1992; 40: 210a
35. Means RT, Dessypris EN, Krantz SB. Inhibition of human erythroid colony forming unit by interleukin-1 is mediated by γ Interferon. J Cell Physiol 1992; 150: 59
36. Blumenstein M, Schidt B, Ward RA. Altered interleukin-1 production in patients undergoing hemodialysis. Nephron 1988; 50: 277-281